IBN Stock Analysis: ICICI Bank | NYSE
Banks - Regional | NYSE, USA | Market Cap: 105.627m USD | 12M Return: -11% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 197M
EPS Trend: 90.3%
Qual. Beats: 1
Rev. Trend: 91.8%
Qual. Beats: 0
Warnings
No concerns identified
Tailwinds
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
ICICI Bank Limited is an Indian financial services group that provides a wide range of banking and related services to retail and corporate customers in India and abroad. Its operations are organized across multiple segments, including Retail Banking, Wholesale Banking, Treasury, Life Insurance, General Insurance, and Other Banking activities. Founded in 1955 and headquartered in Mumbai, the bank is listed in the U.S. through ADRs trading on the NYSE under the ticker IBN.
The companys offerings span the full retail and commercial banking stack: deposit accounts (savings, salary, current, fixed, and foreign currency accounts), lending products (home, auto, personal, education, gold, commercial, working capital, and trade finance), credit and debit cards, digital wallets, investment and broking services, and wealth management. Beyond traditional banking, ICICI also provides life and general insurance, asset management, custodial services, trusteeship, and venture capital fund management, making it one of Indias large diversified private-sector banks.
Indian diversified banks like ICICI typically derive revenue from a mix of net interest income (the gap between loan and deposit rates) and fee-based income from cards, distribution, transaction banking, and insurance, which helps diversify earnings across the credit cycle. The Indian banking sector remains structurally supported by a large under-banked retail population, growing credit penetration, and the countrys broader role as an emerging-market financial center.
- RBI rate cuts compress net interest margins on lending portfolio
- Retail loan growth accelerates in mortgages and personal credit
- Insurance subsidiaries deliver rising fee income and dividends
| Net Income: 562b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.02 > 0.02 and ΔFCF/TA -0.78 > 1.0 |
| NWC/Revenue: -558.6% < 20% (prev -478.4%; Δ -80.13% < -1%) |
| CFO/TA 0.02 > 3% & CFO 673b > Net Income 562b |
| Net Debt (298b) to EBITDA (823b): 0.36 < 3 |
| Current Ratio: 0.11 > 1.5 & < 3 |
| Outstanding Shares: last quarter (3.63b) vs 12m ago 0.08% < -2% |
| Gross Margin: 68.53% > 18% (prev 68.07%; Δ 0.46% > 0.5%) |
| Asset Turnover: 10.57% > 50% (prev 11.31%; Δ -0.74% > 0%) |
| Interest Coverage Ratio: 0.89 > 6 (EBIT TTM 792b / Interest Expense TTM 892b) |
| A: -0.56 (Total Current Assets 1965b - Total Current Liabilities 18704b) / Total Assets 30024b |
| B: 0.05 (Retained Earnings 1483b / Total Assets 30024b) |
| C: 0.03 (EBIT TTM 792b / Avg Total Assets 28355b) |
| D: 0.15 (Book Value of Equity 3805b / Total Liabilities 26043b) |
| Altman-Z'' = -3.16 = D |
As of July 28, 2026, the stock is trading at USD 29.89 with a total of 3,330,562 shares traded. Over the past week, the price has changed by +0.44%, over one month by +1.81%, over three months by +8.53% and over the past year by -10.97%.
Current recommended Stop Loss: 28.40 (which is 5% or 2.7 ATR below the current price).
ICICI Bank has received a consensus analysts rating of 4.75. Therefore, it is recommended to buy IBN.
- StrongBuy: 3
- Buy: 1
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 35.8 | 19.9% |
Market Cap INR = 10200b (106b USD * 96.5675 USD.INR)
P/E Trailing = 18.2161
P/E Forward = 17.7936
P/S = 4.5143
P/B = 2.6552
P/EG = 0.5248
Revenue TTM = 2997b INR
EBIT TTM = 792b INR
EBITDA TTM = 823b INR
Long Term Debt = 2263b INR (from longTermDebt, last quarter)
Short Term Debt = 245b INR (from shortLongTermDebt, last fiscal year)
Debt = 2263b INR (from shortLongTermDebtTotal, last quarter)
Net Debt = 298b INR (calculated: Debt 2263b - CCE 1965b)
Enterprise Value = 10498b INR (10200b + Debt 2263b - CCE 1965b)
Interest Coverage Ratio = 0.89 (Ebit TTM 792b / Interest Expense TTM 892b)
EV/FCF = 16.51x (Enterprise Value 10498b / FCF TTM 636b)
FCF Yield = 6.06% (FCF TTM 636b / Enterprise Value 10498b)
FCF Margin = 21.22% (FCF TTM 636b / Revenue TTM 2997b)
Net Margin = 18.75% (Net Income TTM 562b / Revenue TTM 2997b)
Gross Margin = 68.53% ((Revenue TTM 2997b - Cost of Revenue TTM 943b) / Revenue TTM)
Gross Margin QoQ = 60.34% (prev 73.64%)
Tobins Q-Ratio = 0.35 (Enterprise Value 10498b / Total Assets 30024b)
Interest Expense / Debt = 39.41% (Interest Expense 892b / Debt 2263b)
Taxrate = 24.49% (194b / 793b)
NOPAT = 598b (EBIT 792b * (1 - 24.49%))
Current Ratio = 0.11 (Total Current Assets 1965b / Total Current Liabilities 18704b)
Debt / Equity = 0.59 (Debt 2263b / totalStockholderEquity, last quarter 3805b)
Debt / EBITDA = 0.36 (Net Debt 298b / EBITDA 823b)
Debt / FCF = 0.47 (Net Debt 298b / FCF TTM 636b)
Total Stockholder Equity = 3570b (last 4 quarters mean from totalStockholderEquity)
RoA = 1.98% (Net Income 562b / Total Assets 30024b)
RoE = 15.74% (Net Income TTM 562b / Total Stockholder Equity 3570b)
RoCE = 13.58% (EBIT 792b / Capital Employed (Equity 3570b + L.T.Debt 2263b))
RoIC = 5.36% (NOPAT 598b / Invested Capital 11171b)
WACC = 11.05% (E(10200b)/V(12463b) * Re(6.90%) + D(2263b)/V(12463b) * Rd(39.41%) * (1-Tc(0.24)))
Discount Rate = 6.90% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 90.80 | Cagr: 0.74%
[DCF] Terminal Value 63.73% ; FCFF base≈691b ; Y1≈606b ; Y5≈490b
[DCF] Fair Price = 1.44k (EV 5454b - Net Debt 298b = Equity 5156b / Shares 3.59b; r=11.05% [WACC]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: 90.27 | EPS CAGR: 7.25% | SUE: 1.16 | # QB: 1
Revenue Correlation: 91.76 | Revenue CAGR: 17.59% | SUE: 0.47 | # QB: 0
EPS current Quarter (2026-09-30): EPS=0.38 | Chg30d=-2.54% | Revisions=-25% | Analysts=1
EPS next Quarter (2026-12-31): EPS=0.38 | Chg30d=-6.60% | Revisions=-25% | Analysts=1
EPS current Year (2027-03-31): EPS=1.60 | Chg30d=-5.36% | Revisions=-40% | GrowthEPS=+6.9% | GrowthRev=+14.9%
EPS next Year (2028-03-31): EPS=1.85 | Chg30d=-3.19% | Revisions=-25% | GrowthEPS=+15.6% | GrowthRev=+15.0%